ХАРРИС Кит Джон (US),АГАР Жуаси К. (US),ШУМ Патрик Ваи-Квок (US),ЧЖАО Чжичэн (US),ПОЛИ Грегори Б. (US),СТОКЛОЗА Грегори Т. (US),ЧОИ-СЛЕДЕСКИ Йонг-Ми (US),РАЙЛИНГ Штефан (US)
申请号：
RU2012143978/04
公开号：
RU2012143978A
申请日:
2011.03.15
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. The compound of formula (I) or its chiral enantiomer, or its ester prodrug or a pharmaceutically acceptable salt. A compound according to claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, phosphate, hemifumarate, fumarate, hemitartrate, tartrate, maleate and sulfate. The compound of claim 2, wherein the pharmaceutically acceptable salt is phosphate. A pharmaceutical composition comprising a pharmaceutically effective dosage amount of a compound according to claim 1 in a mixture with a pharmaceutically acceptable carrier. A method of treating a patient suffering from allergic disorder, bronchial asthma, allergic rhinitis, allergic dermatitis, macular degeneration, wet macular degeneration, dry macular degeneration, allergic conjunctivitis or chronic obstructive pulmonary disease, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.6. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 1 and a compound selected from the group consisting of an antihistamine, a leukotriene antagonist, a beta agonist, a PDE4 inhibitor, a TP antagonist and a CrTh2 antagonist, in admixture with a pharmaceutically acceptable carrier. The pharmaceutical composition according to claim 6, wherein the antihistamine is fexofenadine, loratadine, cetirizine or levocetirizine； the leukotriene antagonist is montelukast or zafirlukast； the beta agonist is albuterol, salbuterol or terbutaline； the PDE4 inhibitor is roflumilast or cilomilast； the TP antagonist is ramatroban, and the CrTh2 antagonist is1. Соединение формулы (I)или его хиральный энантиомер,или его сложноэфирное пролекарство или фармацевтически приемлемая соль.2. Соединение по п.1, где фармацевтически приемлемая соль выбрана из группы, включающей гидрохлорид, фосфат, гемифумарат, фумарат, гемитартрат, тартрат, малеат и сульфат.3. Соединение по п.2, где фармацевти
